How did COYA's Q4 2024 expenses impact its revenue?

Coya Therapeutics Inc. (COYA) experienced significant expenses in Q4 2024, which had a notable impact on its revenue.

1. **R&D Expenses**: The company incurred $1.94 million in R&D expenses. This indicates a substantial investment in research and development, which is crucial for a biotech or pharmaceutical company seeking to innovate and bring new products to market.

|code|Ticker|Name|Date|R&D Expenses|R&D Expenses YoY|market_code|
|---|---|---|---|---|---|---|
|COYA|COYA.O|Coya Therapeutics|2024 Q1|3163159|156.80995232651787|186|
|COYA|COYA.O|Coya Therapeutics|2024 Q2|4566152|222.02444088375347|186|
|COYA|COYA.O|Coya Therapeutics|2024 Q3|2223903|39.67204527983359|186|
|COYA|COYA.O|Coya Therapeutics|2024 Q4|1937440|7.46736912287825|186|

2. **Sales and Marketing Expenses**: COYA's selling, general, and administrative (SG&A) expenses totaled $4.29 million, with $2.14 million specifically attributed to SG&A. These expenses are likely related to the costs of selling and marketing the company's products or services.

3. **Administrative Expenses**: The company also had $2.14 million in administrative expenses, which could include a variety of costs such as salaries, rent, and other overhead expenses.

4. **Revenue**: During the same quarter, COYA generated $1.95 million in revenue. This revenue figure is significantly lower than the combined expenses, indicating that the company operated at a loss in Q4 2024.

|code|Ticker|Name|Date|Total Revenue YoY|Total Revenue|market_code|
|---|---|---|---|---|---|---|
|COYA|COYA.O|Coya Therapeutics|2024 Q1||126838|186|
|COYA|COYA.O|Coya Therapeutics|2024 Q2||3425271|186|
|COYA|COYA.O|Coya Therapeutics|2024 Q4|-99.96747862369268|1952|186|

In conclusion, COYA's Q4 2024 expenses far exceeded its revenue, resulting in a substantial financial loss for the company. The high R&D expenses are a strategic investment, but they need to be balanced with the company's revenue generation capabilities to ensure long-term sustainability.